

HI 2025 FINANCIAL RESULTS

August 19, 2025

PRECISION TO THE POINT



SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

AGENDA

1. HI 2025 AT A GLANCE
2. FINANCIAL REVIEW
3. OUTLOOK
4. Q&A



HI 2025 AT A GLANCE

HIGHLIGHTS AND ACHIEVEMENTS



Return to sales **growth** thanks to **high development activity** and further **stabilization** in **system** demand



Stable gross margin development overshadowed by **negative currency effects**



Progress in **development partnerships** and significant **upturn** in the **deal pipeline** in the area of **system development**



Full year outlook confirmed

.... developments in **HI/2025** inline with intra-year **expectations**

FINANCIAL REVIEW

FINANCIALS AT A GLANCE¹

€ 000s	H1/2025	H1/2024 ²	Change	Q2/2025	Q2/2024 ²	Change
Sales	118,590	112,691	+5.2% (cc: +5.8%)	58,227	58,803	-1.0% (cc: +0.9%)
Adjusted EBITDA	16,070	17,426	-7.8%	6,765	10,834	-37.6%
Adjusted EBITDA margin (%)	13.6	15.5	-190 bps	11.6	18.4	-680 bps
Adjusted EBIT	8,487	9,880	-14.1%	3,124	6,960	-55.1%
Adjusted EBIT margin (%)	7.2	8.8	-160 bps	5.4	11.8	-640 bps
Adjusted consolidated net income	4,978	5,603	-11.2%	1,823	4,539	-59.8%
Adjusted basic earnings per share (in €)	0.41	0.46	-10.9%	0.15	0.37	-59.5%
Basic earnings per share IFRS (in €)	0.21	0.33	-36.4%	0.09	0.31	-71.0%

bps = basis points
cc = at constant currency

¹ To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses).

² Restated pursuant to IAS 8.

FINANCIAL REVIEW

ADJUSTMENTS HI/2025

EBIT

€ 000s	HI/2025	HI/2024 ²
Adjusted EBIT	8,487	9,880
Adjustments:		
PPA amortization	-1,617	-1,871
Other ¹	-1,551	-120
EBIT	5,319	7,889

¹ Including one-off advisory expenses, fees, and restructuring expenses

² Restated pursuant to IAS 8

Consolidated net income


€ 000s	HI/2025	HI/2024 ²
Adjusted consolidated net income	4,978	5,603
Adjusted earnings per share in € (basic)	0.41	0.46
Adjustments:		
PPA amortization	-1,617	-1,871
Other ¹	-1,551	-120
Taxes on income	792	434
Consolidated net income	2,602	4,046
Earnings per share in € (basic)	0.21	0.33

¹ Including one-off advisory expenses, fees, and restructuring expenses

² Restated pursuant to IAS 8

FINANCIAL REVIEW

SALES HI/2025



cc = at constant currency

HI/2024 restated pursuant to IAS 8


As of June 30

HI/2025 sales +5.8% yoy in constant currency to € 118.6 million


- Resilient growth with Service Parts and consumables
 - Increased recognition of Development and service sales
-
- Subdued ramp-up curves for newly launched products
 - Low but stabilizing demand for MDx systems following pandemic related disruptions

SALES BY OPERATING DIVISIONS H1/2025

Sales in € million



In % of total sales




cc = at constant currency

H1/2024 restated pursuant to IAS 8

As of June 30

FINANCIAL REVIEW

ADJUSTED EBIT AND EBIT MARGIN H1/2025



H1/2024 restated pursuant to IAS 8

As of June 30

H1 2025 adj. EBIT -14.1% to 8.5 million €

Margin -160 bps YoY to 7.2%

- Stable gross margin development despite lack of scale and subdued product mix in the systems business
 - Gross margin at 26.9% (H1/2024: 27.1%)
 - Efficiency measures and structural changes taking effect

- Negative valuation effects resulting from currency translation of balance sheet items

€ 000s	H1/2025	H1/2024
Research and development expenses	-5,425	-5,560
Sales-related expenses	-6,507	-6,852
General administrative expenses	-12,988	-11,260
Income / Expenses from impairment of financial assets and contract assets	-418	+9
Other operating income and expenses	-1,298	+1,006

FINANCIAL REVIEW

CASH FLOW AND NET DEBT

€ 000s	H1/2025	H1/2024	Change
Cash flow – operating activities	-5,771	17,381	nm
Cash flow – investment activities	-8,960	-8,773	nm
Cash flow – financing activities	-12,413	-11,627	nm
Free cash flow	-14,731	8,608	nm

€ 000s	H1/2025	FY/2024	Change
Cash	18,698	47,164	-60.4%
Equity ratio (%)	56.0	54.5	+150 bps
Net debt	110,005	87,096	+26.3%

- **Operating cash flow dynamics** burdened by high cash tax payments, decrease in trade payables and not yet materialized inventory reduction
- Strong focus to **reduce still elevated inventory** levels going forward

€ 000s	H1/2025	FY/2024
Inventories	125,114	121,818
Trade receivables	40,357	41,578
Trade payables	14,742	18,447

- **Investment ratio¹** at **7.6%** of sales below projected corridor for FY 2025 of 8.0% to 10.0%
- **Net debt / LTM adj. EBITDA** at **2.3x** (up from 1.8x at the end of FY 2024)
- Negotiations on **refinancing of existing bridge** loan by a new syndicated loan is ongoing (closing slightly postponed; **signing** now expected for **end of August**)

¹ Total investments in intangible and tangible assets in % of sales

FINANCIAL GUIDANCE FOR FISCAL YEAR 2025



Consolidated sales for the 2025 financial year expected to grow in a low to medium single-digit percentage range on a constant-currency basis

Current order forecasts from customers indicate increasing momentum in the systems business in the second half of the year

Adjusted EBIT margin of 10.0% to 12.0% (FY 2024: 13.0%)

Higher earnings contribution from higher-margin development and services sales expected for the fourth Quarter 2025

Better scale effects due to better utilization in the systems business within H2/2025



Investments in tangible and intangible assets combined of around 8.0% to 10.0% of sales (FY 2024: 7.1%)

Higher investments for development projects and IT

OUTLOOK

FOCUS IN 2025 AND BEYOND

Maintaining cost discipline throughout the company given earnings improvement measures implemented

Continue to **grow footprint** in selected **market focus areas** (High-Sensitivity Immunoassays, Advanced Imaging, Cell & Gene Therapy)

Manage and process **well filled M&A pipeline** according to external growth and diversification strategy


Execute deal pipeline regarding new development and manufacturing agreements

Continue **leveraging** the **combined customer base** of both, **STRATEC** and **Natech**

Improve **cash flow dynamics** with **strong focus** on **inventory efficiency**



WE ARE HAPPY TO SUPPORT



QUESTIONS ANSWERS

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone +49 7082 7916-0
Fax +49 7082 7916-999
www.strattec.com

CONTACT

Jan Keppeler, CFA
Head of Investor Relations, Sustainability & Corporate
Communications

Phone +49 7082 7916-6515
j.keppeler@strattec.com



THANK YOU
FOR YOUR
ATTENTION